Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

1.

Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.

Floren LC, Wiznia A, Hayashi S, Jayewardene A, Stanley K, Johnson G, Nachman S, Krogstad P, Aweeka FT; Pediatric AIDS Clinical Trials Group 377 Protocol Team.

Pediatrics. 2003 Sep;112(3 Pt 1):e220-7.

PMID:
12949316
[PubMed - indexed for MEDLINE]
2.

Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP.

Pediatr Infect Dis J. 2005 Oct;24(10):880-5.

PMID:
16220085
[PubMed - indexed for MEDLINE]
3.

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

Krogstad P, Lee S, Johnson G, Stanley K, McNamara J, Moye J, Jackson JB, Aguayo R, Dieudonne A, Khoury M, Mendez H, Nachman S, Wiznia A; Pediatric AIDS Clinical Trials Group 377 Study Team.

Clin Infect Dis. 2002 Apr 1;34(7):991-1001. Epub 2002 Feb 27.

PMID:
11880966
[PubMed - indexed for MEDLINE]
Free Article
4.

Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.

Skowron G, Leoung G, Hall DB, Robinson P, Lewis R, Grosso R, Jacobs M, Kerr B, MacGregor T, Stevens M, Fisher A, Odgen R, Yen-Lieberman B.

J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):351-8.

PMID:
15097151
[PubMed - indexed for MEDLINE]
5.

The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.

Merry C, Barry MG, Mulcahy F, Ryan M, Tjia JF, Halifax KL, Breckenridge AM, Back DJ.

AIDS. 1998 Jul 9;12(10):1163-7.

PMID:
9677165
[PubMed - indexed for MEDLINE]
6.

Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).

Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P.

J Infect Dis. 2001 Jun 15;183(12):1732-8. Epub 2001 May 16.

PMID:
11372025
[PubMed - indexed for MEDLINE]
Free Article
7.
8.

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.

Grub S, Delora P, Lüdin E, Duff F, Fletcher CV, Brundage RC, Kline MW, Calles NR, Schwarzwald H, Jorga K.

Clin Pharmacol Ther. 2002 Mar;71(3):122-30. Review.

PMID:
11907486
[PubMed - indexed for MEDLINE]
9.

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.

Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA; ESS40002 Study Team.

HIV Med. 2006 Mar;7(2):85-98.

PMID:
16420253
[PubMed - indexed for MEDLINE]
10.

Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.

Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.

Antivir Ther. 2004 Apr;9(2):197-204.

PMID:
15134181
[PubMed - indexed for MEDLINE]
11.

Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.

Riddler SA, Havlir D, Squires KE, Kerr B, Lewis RH, Yeh K, Wynne LH, Zhong L, Peng Y, Deutsch P, Saah A.

Antimicrob Agents Chemother. 2002 Dec;46(12):3877-82.

PMID:
12435691
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

Gathe JC Jr, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J.

AIDS. 2004 Jul 23;18(11):1529-37.

PMID:
15238771
[PubMed - indexed for MEDLINE]
13.

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.

INITIO Trial International Co-ordinating Committee, Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, Floridia M, Girard PM, Goodall RL, Hooker MH, Mijch A, Meiffredy V, Salzberger B.

Lancet. 2006 Jul 22;368(9532):287-98.

PMID:
16860698
[PubMed - indexed for MEDLINE]
14.

Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.

Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, Morse EV, Krogstad PA, Nachman S; Pediatric AIDS Clinical Trials Group Adherence Subcommittee Pediatric AIDS Clinical Trials Group 377 Study Team.

Pediatrics. 2002 Apr;109(4):e61.

PMID:
11927734
[PubMed - indexed for MEDLINE]
15.

Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.

Capparelli EV, Sullivan JL, Mofenson L, Smith E, Graham B, Britto P, Becker MI, Holland D, Connor JD, Luzuriaga K; Pediatric ACTG 356 Investigators.

Pediatr Infect Dis J. 2001 Aug;20(8):746-51.

PMID:
11734735
[PubMed - indexed for MEDLINE]
16.

Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.

Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, Watts DH, Huang S, Hughes MD, Kaiser K, Purdue L, Asfaw Y, Keller M, Smith E; PACTG 353 Team.

HIV Clin Trials. 2008 Mar-Apr;9(2):115-25. doi: 10.1310/hct0902-115.

PMID:
18474496
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.

Baroncelli S, Villani P, Floridia M, Pirillo MF, Galluzzo CM, Cusato M, Amici R, Pinnetti C, Sabbatini F, Molinari A, Tamburrini E, Regazzi M.

Ther Drug Monit. 2008 Oct;30(5):604-10. doi: 10.1097/FTD.0b013e3181867a6e.

PMID:
18728627
[PubMed - indexed for MEDLINE]
18.

The pharmacokinetics of nelfinavir in HIV-1-infected children.

van Heeswijk RP, Scherpbier HJ, de Koning LA, Heymans HS, Lange JM, Beijnen JH, Hoetelmans RM.

Ther Drug Monit. 2002 Aug;24(4):487-91.

PMID:
12142631
[PubMed - indexed for MEDLINE]
19.

Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.

Gatti G, Castelli-Gattinara G, Cruciani M, Bernardi S, De Pascalis CR, Pontali E, Papa L, Miletich F, Bassetti D.

Clin Infect Dis. 2003 Jun 1;36(11):1476-82. Epub 2003 May 21.

PMID:
12766843
[PubMed - indexed for MEDLINE]
Free Article
20.

Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.

Read JS, Best BM, Stek AM, Hu C, Capparelli EV, Holland DT, Burchett SK, Smith ME, Sheeran EC, Shearer WT, Febo I, Mirochnick M.

HIV Med. 2008 Nov;9(10):875-82. doi: 10.1111/j.1468-1293.2008.00640.x. Epub 2008 Sep 14.

PMID:
18795962
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk